1	The impact of diabetes mellitus and HBV infection on major
2	adverse cardiovascular events related to statin use for Chinese
3	population with cardiovascular disease
4	Running title: Effect of DM or HBV infection on MACEs.
5	
6	Qian Wu ^a , MM; Xiaoxuan He ^a , MM; Xiaoning Tong ^a , MM; Ying Li ^b , MM; Xiaoqin
7	Wang ^a , MD
8	^a Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong
9	University, Xi'an, 710061, Shaanxi Province, China.
10	^b Department of Clinical Laboratory, Shaanxi Kang Fu Hospital, Xi'an,710065,
11	Shaanxi Province, China.
12 13	Qian Wu and Xiaoxuan He contributed equally to this work.
14	
15	Correspondence to: Dr. Xiaoqin Wang, M.D. Department of Clinical Laboratory,
16	The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road,
17	Xi'an 710061, Shaanxi Province, China. E-mail: wq710641296@xjtufh.edu.cn.
18	
19	Clinical Perspective
20	What Is New?
21	• This study investigates the association between statin therapy and major adverse
22	cardiovascular events (MACEs) in Chinese patients with cardiovascular disease who
23	have concurrent hepatitis B virus infection or diabetes mellitus.
24	• The findings suggest potential cardiovascular benefits of statin therapy in this
25 _{NO}	TELTHIS preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- The study explores the relationship between statin use and changes in hepatic
- 27 function, atherosclerotic markers, and inflammatory parameters.

28 What Are the Clinical Implications?

- The results provide evidence supporting statin use in cardiovascular disease patients
- 30 with hepatitis B virus infection or diabetes mellitus.
- Glycemic control appears to be an important factor in optimizing cardiovascular
- 32 outcomes in these patients.
- Regular monitoring of hepatic and inflammatory markers may be valuable in
- 34 assessing treatment response.

BACKGROUND: The association between hepatitis B virus (HBV) infection, diabetes mellitus
(DM) and cardiovascular disease (CVD) remains uncertain. This study was aimed to investigate
the impact of HBV infection and DM on 13 major adverse cardiovascular events (MACEs) among
CVD patients with or without statin use.

39 **METHODS AND RESULTS:** In total, 45,013 individuals participated in the baseline survey between June 2020 and August 2023. The patients were categorized into two groups according to 40 their surface antigen status. Finally, a sample size of 496 participants was included in the study: 41 42 patients with coexisting CVD and HBV (n = 225) and patients with CVD alone (n = 271). The 43 implementation of statins has demonstrated the potential to reduce the incidence of coronary heart 44 disease (CHD) and angina pectoris (AP) in individuals with CVD who are also affected by HBV 45 infection. The analysis of stratification, taking into account the presence of DM, has demonstrated 46 a significant increased vulnerability to myocardial infarction (MI), acute myocardial infarction 47 (AMI), and heart failure (HF) among individuals with HBV infection combined with CVD. DM and hemoglobin A1c (HBA1c) level of ≥ 6 are identified as risk factors for the development of 48 CHD, MI, AP, and hypertension. Our study also suggests that statin therapy led to a 49 50 dose-dependent decrease in liver fibrosis, as well as improvement of the atherogenicity index and 51 systemic inflammatory response in patients with CVD.

52 **CONCLUSION:** Our study indicates that CVD patients who also have HBV infection or DM 53 may experience a reduction in MACEs when treated with statins. Furthermore, our research 54 indicates that focusing on long-term glycemic control is essential in this patient population in 55 order to enhance cardiovascular outcomes. The observed improvements in hepatic function, 56 atherosclerotic burden, and systemic inflammation associated with statin therapy may contribute 57 to the favorable cardiovascular outcomes among individuals with CVD.

Key Words: HBV
diabetes mellitus
CHD
cardiovascular disease
statins use 58 Coronary heart disease (CHD) is the primary cause of mortality in humans, 59 accounting for approximately 9 million deaths annually worldwide¹. CHD 60 encompasses cardiovascular conditions resulting from the narrowing or obstruction of 61 the coronary arteries due to atherosclerosis, as well as myocardial ischemia, hypoxia, 62 or necrosis caused by functional alterations in these arteries². Presently, there exists a 63 prevailing belief within the academic community that the presence of obesity, 64 smoking, and alcohol consumption plays a substantial role in the advancement of 65 CHD^{3, 4}. Furthermore, it is worth emphasizing that hypertension, hyperlipidemia, 66 hypercholesterolemia, and diabetes mellitus (DM) also contribute to the development 67 of CHD ⁵⁻⁸. Notably, DM represents a significant risk factor, as the elevated blood 68 69 glucose levels experienced by individuals with this condition often induce oxidative stress and inflammatory harm, ultimately resulting in atherosclerosis, coronary artery 70 dysfunction, myocardial infarction, and cellular impairment, thereby fostering the 71 progression of CHD ⁹. DM is additionally linked to an unfavorable long-term 72 prognosis in individuals diagnosed with CHD. In comparison to patients without DM, 73 those with DM complicated by CHD exhibit a higher mortality rate over a span of 10 74 years 10^{10} . 75

The global prevalence of Hepatitis B virus (HBV) infection is substantial, rendering it
a significant concern for public health. Prolonged HBV infection can result in chronic
hepatitis, cirrhosis, liver decompensation, and hepatocellular carcinoma ¹¹. Chronic
HBV infection is characterized by a state of inflammation, which has been observed

to elevate the likelihood of major adverse cardiovascular events (MACE) and 80 cerebrovascular disease in other conditions featuring chronic low-grade inflammation 81 ^{12, 13}. Several studies have examined the association between HBV infection and 82 cardiovascular disease (CVD); however, the findings have been inconclusive ¹⁴⁻¹⁷. 83 Certain studies have identified a positive correlation between HBV infection and 84 coronary artery disease ¹⁷, whereas others have indicated a negative correlation ¹⁴⁻¹⁶. 85 In individuals diagnosed with chronic viral hepatitis, it has been observed that those 86 with HCV infection exhibit a notably elevated susceptibility to composite arterial 87 events and all-cause mortality when compared to those with HBV infection ^{18, 19}. 88 Furthermore, investigations have indicated that there is no substantial association 89 between the prevalence of macrovascular complications, microvascular complications 90 91 of diabetes, diabetic ketosis, or diabetic ketoacidosis and the status of HBV infection 20 . Hence, it is crucial to persist in the examination of the correlation between HBV 92 infection and MACE. 93

Statins have demonstrated efficacy in mitigating the occurrence of CVD and are 94 endorsed as the primary therapeutic approach for hypercholesterolemia in clinical 95 guidelines^{21, 22}. The American College of Cardiology/American Heart Association 96 guidelines for managing blood cholesterol levels to minimize the risk of 97 atherosclerotic CVD (ASCVD) in adults have classified statins into low, moderate, 98 and high potency categories, based on comprehensive analysis of their lipid-lowering 99 effects across various clinical trials and direct comparisons. High-potency statins, 100 such as rosuvastatin at doses of 20 mg/d and 40 mg/d, and atorvastatin at doses of 40 101

mg/d and 80 mg/d, have exhibited a noteworthy decrease in low-density lipoprotein 102 cholesterol (LDL-C) levels surpassing 50%²¹. Additionally, decreased cholesterol 103 levels by statin use may impact the advancement of hepatic fibrosis by ameliorating 104 portal hypertension and reducing the excessive accumulation of hepatic triglycerides 105 ²³⁻²⁵. Numerous clinical studies have demonstrated the efficacy of statin 106 administration in patients with NAFLD, leading to improvements in liver 107 ultrasonography and liver function tests ²⁶⁻²⁸. The independent association of statin 108 use with reductions in hepatic steatosis and fibrosis stage in NAFLD patients has also 109 been observed ^{26, 28}. The pathogenesis of hepatic fibrosis is characterized by a 110 multifaceted interaction between lipid metabolism and systemic chronic inflammatory 111 response in patients with CVD $^{29, 30}$. 112

113 Hence, this study aimed to gather data on patients with both HBV and CVD, as well as those with CVD alone, in order to examine the correlation between statin use and 114 HBV infection, DM, or hemoglobin A1c (HbA1c) levels among individuals with 115 CVD. Additionally, the study sought to assess the impact of HBV infection, DM, 116 HbA1c levels, or statin use on various cardiovascular outcomes in patients with CVD. 117 Currently, there is uncertainty regarding the impact of statins on hepatic fibrosis and 118 systemic inflammatory response, as well as their effects on CVD and lipid 119 metabolism. The identification of specific markers in this context remains ambiguous. 120 It is our assertion that the identification of suitable markers is crucial for the 121 monitoring of liver fibrosis and systemic inflammation in patients with CVD 122 undergoing statin therapy. Our research aimed to assess the impact of statin therapy 123

124 on hepatic fibrosis, systemic inflammation, and atherogenic indices in patients with

125 CVD.

126

127 MATERIALS AND METHODS

128 Study design and participants

A prospective cohort study was conducted to examine the prevalence, incidence, and 129 associated factors, such as HBV infection, in relation to CVD. The study was 130 approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong 131 University (No:XJTU1AF2024LSYY-054). In total, 45,013 individuals participated in 132 133 the baseline survey at the First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China) between June 2020 and August 2023. Of these, 43,750 cases were excluded 134 due to HCV, HIV, syphilis infection, as well as incomplete basic data of test results 135 136 and medical records. A total of 268 patients presenting with hepatic hemangioma, toxic diffuse goiter with hyperthyroidism, hypothyroidism, endometrial cancer, stage 137 5 hemodialysis status of chronic kidney disease, chronic renal insufficiency, skull 138 osteoma, and right lobe cyst of thyroid gland were excluded from the study. 139 Additionally, 499 cases with incomplete test data, including five quantitative variables 140 (disease load, blood cells, blood lipid, and other information), as well as incomplete 141 drug use information, were also excluded. Consequently, a final sample size of 496 142 participants was included in the study (refer to Figure 1). The patients were 143 categorized into two groups according to their surface antigen status: patients with 144 coexisting CVD and HBV (n = 225) and patients with CVD alone (n = 271). In 145 addition, a sample size of 494 CVD participants was included, patients with statin use 146

147 (n = 415) and statin-free (n = 79), to investigate the effect of statin use on hepatic 148 fibrosis, atherosclerotic burden, and systemic inflammation.

149 Clinical data collection and measurements

The variables considered in this study encompassed patient demographics such as age 150 and gender, as well as medical factors including hypertension, smoking/alcohol 151 consumption, diabetes, disease status, biochemical indicators, blood cell indicators, 152 HBV five-item quantitative, HBV-DNA quantitative, statin use, antiviral therapy for 153 hepatitis B, and major adverse cardiovascular events. The ratios of platelet count to 154 155 lymphocyte count (PLR) and neutrophil count to lymphocyte count (NLR) are computed to assess certain adverse cardiovascular events, such as recurrent angina 156 pectoris (AP), hospitalization for unstable angina pectoris (UAP), acute myocardial 157 158 infarction (AMI), severe arrhythmia, heart failure (HF), and death due to CHD. Major adverse cardiovascular events include recurrent AP, UAP requiring hospitalization, 159 AMI, severe arrhythmia, HF, coronary-related death, etc. Secondary adverse 160 161 cardiovascular events include Killip classification II-IV or NYHA Classification II-IV. 162

All specimens were tested within 2 hours following their collection. In cases where immediate testing was not feasible, specimens were stored at a temperature of -20°C for a duration not exceeding 2 days. The fluorescence quantitative PCR detection of HBV-DNA load was conducted utilizing the 7500 fluorescence quantitative PCR instrument and associated reagents (ABI, USA). Quantitative determination of biochemical indicators was performed using the Roche AU5600 automatic

biochemical analyzer and its corresponding original reagents. The quantification of 169 the five components of serum hepatitis B was performed using the i2000sr instrument 170 171 manufactured by Abbott Laboratories, USA. The detection of blood cell indicators was conducted using the routine automatic flow cytometer Mindray CAL8000. The 172 Roche E801 automatic immunoassay analyzer, along with original reagents, was 173 utilized for the quantitative determination of B-type natriuretic peptide (BNP) in the 174 anterior brain. HbA1c was assessed with high-performance liquid chromatography. 175 All aforementioned measurements were performed in accordance with the 176 177 manufacturer's instructions.

Calculations of the albumin-bilirubin index (ALBI) score, fibrosis 4 index (FIB-4) 178 index, complete blood count derived inflammation index (CBCIIs) and 179 180 atherogenic indices. Non-invasive and non-destructive testing markers, including FIB-4, ALBI, CBCIIs, such platelet monocyte and as ratio (PMR), 181 neutrophil/lymphocyte ratio (NLR), SII, systemic inflammatory response index (SIRI), 182 and aggregate index of systemic inflammation, and atherogenic indices, such as 183 atherogenic index of plasma (AIP), atherogenic index (AI), Castelli risk index-I 184 (CRI-I), Castelli risk index-II (CRI-II), and triglyceride-rich lipoprotein cholesterol 185 (TRL-C) were used to evaluate the effects of statin use on hepatic fibrosis, systemic 186 inflammation, and arteriosclerotic degree in patients with CVD. The calculation 187 formulas of hepatic fibrosis indicators ALBI score, FIB-4 index were measured as 188 described previously ³¹. CBCIIs, including SIRI, SII, aggregate index of systemic 189 inflammation (AISI), SIRI/HDL-C, and SIRI×LDL-C, were calculated as described 190

- 191 previously ^{32, 33}. Atherogenic indices, such as adjusted AIP, AIP, AI, CRI-I, CRI-II,
- 192 LCI, and TRL-C, were calculated as described previously ³⁴⁻³⁷.

193 Statistical analysis

In the case of measurement data that conforms to a normal distribution, the mean \pm 194 standard deviation is employed for representation, and intergroup comparison is 195 carried out through the utilization of a t-test. Conversely, for measurement data that 196 does not adhere to a normal distribution, the median (quartile) [M ($P_{25} \sim P_{75}$)] is 197 employed for representation, and intergroup comparison is conducted using the 198 199 Mann-Whitney U non-parametric test. Count data is represented using frequency and percentage (%), and intergroup comparison is performed using either the chi-square 200 test or Fisher's exact probability method. The Breslow-Day test is employed for 201 202 conformance testing in hierarchical analysis, while the Mantel-Haenszel test is utilized for hierarchical chi-square testing. To address potential confounding, logistic 203 regression models were used to estimate the odds ratio (OR) and 95% CI for MACE. 204 205 All statistical analyses were conducted using SPSS, version 22.0 (SPSS Inc, USA). A 2-tailed *P* value of less than 0.05 was considered to be statistically significant. 206

207 **RESULTS**

Table 1 presents the demographic characteristics of the study participants. A total of
496 subjects were included in the analysis, comprising 225 individuals with pure
CVD and 271 individuals with CVD accompanied by HBV infection. Notably, the
CVD combined with HBV infection group exhibited a statistically significant increase
in the proportion of males and AMI when compared to the CVD alone group (both P

< 0.05). Furthermore, when comparing patients with CVD alone to those with CVD 213 combined with HBV, it was observed that the latter group exhibited elevated levels of 214 215 HBsAg, HbsAb, and HbcAb (all P < 0.05). Conversely, the CVD combined with HBV group displayed lower levels of weight, medication dosage, TG, Lpa, PLR, and 216 PLT in comparison to the CVD alone group. Additionally, the proportions of diabetes 217 and pre-hospital medication were relatively lower in the CVD combined with HBV 218 group. Notably, the remaining indicators presented in Table 1 did not demonstrate 219 statistical significance. The quantitative (Supplementary table 1) and qualitative 220 221 (Supplementary table 2) baseline characteristics and statistical comparisons of individuals with CVD who were either using or not using statins were also 222 documented. It is evident that there are statistically significant differences in height, 223 224 weight, platelet count, alanine aminotransferase levels, and aspartate aminotransferase levels among the three groups (all P < 0.05). The utilization of statins resulted in 225 lower TG (P = 0.000), LDL-C (P = 0.000), ApoB (P = 0.000), and non-HDL-C (P = 226 227 0.000) levels. Based on the findings presented in **Supplementary table 2**, it is evident that there exist statistically significant disparities in gender, diabetes, and smoking 228 history across the three groups, with or without statin usage (all P < 0.05). It is worth 229 noting that long-term use of statins has been associated with an increased risk of DM 230 ³⁸. Consequently, clinicians may be avoiding prescribing statins to cardiovascular 231 patients with diabetes, leading to a higher proportion of non-statin use in this 232 population (65.8%). Conversely, no statistically significant variations were observed 233 in hypertension, alcohol history, and anti-HBV treatment among the three groups (all 234

235 P > 0.05).

236	Relationship of Statin Use with HBV Infection and Quantification. To examine
237	the relationship between statin use and HBV infection, we conducted a study
238	comparing HBV infection rates and quantitative parameters in patients both with and
239	without statin use. Our analysis revealed a significant association between statin use
240	and HBV infection rates ($\chi^2 = 76.835$, $P = 0.000$). Subsequent pairwise comparisons
241	demonstrated that the HBV infection rate in the group not using statins was 97.5%
242	(77/79), whereas the rate in the group using a torvastatin 20 mg was 40.4% (91/225),
243	indicating a protective effect with an OR of 0.018 (95% CI: 0.004 - 0.074). In the
244	rosuvastatin 10 mg group, the HBV infection rate was 53.7% (102/190), indicating a
245	potential protective effect with an OR of 0.030 (95% CI: 0.007 - 0.126). Furthermore,
246	the HBV infection rate was 40.4% (91/225) in the atorvastatin 20 mg group and 53.7%
247	(102/190) in the rosuvastatin 10 mg group, demonstrating a statistically significant
248	difference between the two groups ($P = 0.002$). This suggests that the HBV infection
249	rate in the rosuvastatin 10mg group was relatively higher, with an odds ratio of 1.94
250	(95% CI: 1.28 - 2.94) (Table 2). The HbsAg levels ranged from less than 0.05 to 250,
251	the Median Difference (0-1) was calculated to be 70 (95% CI: 26 to 125). Additionally,
252	the Median Difference (0-2) was found to be 63 (95% CI: 18 to 117). These findings
253	indicate that the quantification of HbsAg in individuals using statins is notably
254	reduced compared to those not using statins (Table 3). The analysis of the Median
255	Difference (1-2) yielded a value of 0 (95% CI: 0 to 0), suggesting a lack of
256	statistically significant disparity in the effectiveness of the two statins in reducing

HbsAg quantitation. However, the OR (atorvastatin/rosuvastatin) in Table 2 was 257 calculated as 1.94 (95% CI: 1.28 to 2.94), indicating a lower infection rate associated 258 259 with atorvastatin (Table 3). This apparent contradiction underscores the need for a nuanced interpretation that considers both qualitative and quantitative aspects of the 260 investigation. Furthermore, when compared to the group not using statins, the 261 quantification of HBV-DNA and HBcAb was significantly lower in the statins use 262 group. Conversely, the quantification of HBsAb, HBeAg, and HBeAb was 263 significantly higher in the statins use group (Table 3). In addition, Table 4 264 265 demonstrates a significant dose-effect relationship between statin dosage and HbsAg quantification (P = 0.000), indicating that higher doses result in lower HbsAg levels, 266 with the exception of a slight rebound observed at the highest dose of rosuvastatin 20 267 268 mg. Nevertheless, the limited sample size at this dosage level necessitates further validation of these findings. 269

The impact of HBV infection, stratified by statins use, on multiple clinical 270 271 outcomes among CVD patients. In our study, atorvastatin and rosuvastatin emerge as the prevailing lipid-lowering medications, with atorvastatin 20 mg and rosuvastatin 272 10 mg serving as the primary drug dosage combinations. This particular combination 273 is employed as a stratification factor to examine the impact of HBV infection on 13 274 clinical outcomes among individuals with CVD. According to the findings depicted in 275 Figure 2, it was observed that HBV infection exhibited a protective effect on the 276 occurrence of CHD (OR = 0.27, 95% CI: 0.12 - 0.60; P = 0.001) and AP (OR = 0.56,277 95% CI: 0.36 - 0.86; P = 0.008). Conversely, HBV infection was identified as a risk 278

factor for AMI (OR = 2.24, 95% CI: 1.40 - 3.57; *P* = 0.001). Furthermore, it was determined that HBV infection did not significantly impact the remaining 11 clinical outcomes in individuals with CAD.

The impact of HBV infection, stratified by DM, on multiple clinical outcomes 282 among CVD patients. Given that the prevalence of DM among patients with and 283 without HBV infection was 48.7% and 62.7%, respectively (P = 0.002; Table 1), it is 284 evident that the baseline characteristics were not equivalent. Consequently, the 285 presence of DM may exert an influence on cardiovascular outcomes. In this study, 286 287 DM was employed as a stratified variable to examine the potential impact of HBV infection on clinical outcomes in patients with CVD. The results of our study indicate 288 that the coexistence of DM and HBV infection may significantly increase the risk of 289 290 AMI (OR = 5.37, 95% CI: 2.91 - 9.92; P < 0.001) as well as unfavorable secondary clinical outcomes (OR = 4.34, 95% CI: 2.06 - 9.15; P < 0.001) (Figure 3). These 291 findings suggest the importance of implementing strict blood sugar control and 292 293 anti-HBV therapy in patients with this comorbidity.

The impact of DM and HbA1c ($\geq 6\%$ or < 6%) on multiple clinical outcomes among CVD patients. Based on the baseline characteristics of the population statistics, a comprehensive analysis was conducted on a total of 496 individuals, comprising 273 subjects with DM and 223 subjects without DM. The findings revealed that, in comparison to the non-DM group, the DM group exhibited a notably higher prevalence of hypertension history and the administration of atorvastatin 20 mg dosage (both P < 0.05). Conversely, the prevalence of smoking history,

301	rosuvastatin 10 mg dosage, and overall statin usage were significantly lower in the
302	DM group (all $P < 0.05$). Furthermore, in comparison to the non-DM group, the DM
303	group exhibited elevated levels of MO, NE, MHR, NHR, BNP, ALS, and HbA1c (all
304	P < 0.05). Conversely, the DM group displayed a relatively diminished ApoE level
305	when contrasted with the non-DM group. There were no statistically significant
306	differences observed in various demographic and clinical factors, including age,
307	gender, height, weight, BMI, alcohol consumption history, LDL-C level, TG level,
308	HDL-C level, triglyceride-to-HDL-C ratio, ApoA level, ApoB level, Lp(a) level, TC
309	level, non-HDL-C level, CYS-C level, LY count, PLT count, NLR, PLR, AST/ALT,
310	AST level, TBil level, and ALP level, between the two groups (Supplementary table
311	3 and 4). As shown in Figure 4 , DM poses a significant risk for CHD ($RO = 6.9, 95\%$
312	CI: 3.2-14.9; <i>P</i> < 0.001) among patients with CVD, MI (RO = 2.2, 95% CI: 1.5-3.2; <i>P</i>
313	< 0.001), AP patients who were not prescribed statins prior to admission (RO = 3.5,
314	95% CI: 1.3-9.3; $P = 0.01$), and individuals with hypertension extreme risk (RO = 2.9,
315	95% CI: 2.0-4.2; $P < 0.001$). Among patients who were not prescribed statins prior to
316	admission, those with HbA1c levels ≥ 6 exhibited the highest susceptibility to CHD,
317	as indicated by an OR of 34.4 (95% CI: 4.2 to 283.6). However, it is important to note
318	that the OR results displayed significant variability due to the limited sample size of
319	the CHD group, which consisted of only 14 cases (Figure 5). In addition, HbA1c
320	levels ≥ 6 also be recognized as a significant risk factor of AP patients who were not
321	prescribed statins prior to admission (RO = 1.6, 95% CI: 1.1-2.3; $P = 0.019$) and
322	individuals with hypertension extreme risk (RO = 2.7, 95% CI: 1.9-4.1; $P < 0.001$;

323 **Figure 5**).

Comparison of the effects of atorvastatin and rosuvastatin on multiple clinical 324 325 outcomes in patients with CVD. The Supplementary table 5 presents a comparison of the effects of atorvastatin and rosuvastatin on 13 clinical outcomes in patients 326 diagnosed with CVD. In comparison to patients prescribed atorvastatin, those 327 prescribed rosuvastatin exhibited the higher susceptibility to CHD and CCU, with OR 328 values of 2.1 (95% CI: 1.0 to 4.2; P = 0.047) and 4.1 (95% CI: 2.5 to 6.6; P < 0.001), 329 respectively. Additionally, the proportion of patients with NYHA classification and a 330 lower risk of UAP were 0.51 (95% CI: 0.32 to 0.79; P = 0.003) and 0.62 (95% CI: 331 0.39 to 0.99; P = 0.043), respectively. In comparison to atorvastatin, the 332 administration of rosuvastatin resulted in a statistically significant decrease in the 333 334 median duration of hospitalization by one day, with a 95% CI ranging from 0.0 to 1.0 day (P = 0.001; Supplementary table 6). 335

Interaction of statin use with hepatic FIB-4, complete blood count-derived 336 337 inflammation indexes (CBCIIs) or ALBI grade. The baseline characteristics and statistical comparisons of both quantitative (Supplementary table 7) and qualitative 338 (Supplementary table 8) parameters of individuals with CVD were using or not 339 using statins. Significant differences were observed in height, weight, platelet count, 340 ALT levels, and AST levels among the three groups (all P < 0.05). The use of stating 341 led to a significant decrease in levels of TG, LDL-C, ApoB, and non-HDL-C (all P = 342 0.000) (Supplementary table 7). Analysis of the data in Supplementary table 8 343 reveals statistically significant differences in gender, diabetes, and smoking history 344

among the three groups (all P < 0.05). In order to assess the potential impact of statin 345 use on improving clinical outcomes related to CVD by inhibiting the progression of 346 347 liver fibrosis, we conducted a study to examine the association of different statin drugs and doses with FIB-4 levels in patients with CVD. The findings of our study 348 demonstrated that atorvastatin was associated with lower FIB-4 levels in comparison 349 to non-statin users, whereas rosuvastatin did not exhibit a significant difference in 350 FIB-4 levels compared to non-statin users (Supplementary table 9). Our study also 351 revealed that the use of statins was associated with a reduction in the levels of SIRI 352 353 and SIRI/HDL-C, while also leading to an increase in PMR and SII in patients with CVD (Supplementary table 9). The findings of dose-stratification analysis in CVD 354 patients revealed a correlation between the increased dosage of atorvastatin and 355 356 rosuvastatin and the reduction in FIB-4 levels, suggesting the presence of a dose-response relationship (Supplementary table 10). Concurrently, a FIB-4 357 stratification analysis was conducted, revealing that patients treated with atorvastatin 358 359 exhibited a higher proportion of FIB-4 < 1.45 and a lower proportion of FIB-4 > 3.25. Nevertheless, the reduction in FIB-4 level with rosuvastatin was not as pronounced as 360 with atorvastatin (Supplementary table 11). 361

The ALBI grade is a liver function assessment tool that utilizes measurements of albumin and bilirubin levels. The study examined the impact of statin medications on liver function markers and ALBI grade. Statin use was found to significantly decrease DBIL levels compared to non-statin users, while showing no significant effect on other liver function indices, including ALBI grade (**Supplementary table 12**).

Stratified analysis based on ALBI grade revealed that none of the patients progressed
to an ALBI grade ≥-1.39, indicative of the group with the poorest prognosis.
Furthermore, statin drug use did not influence ALBI grade in the remaining two
groups (Supplementary table 13).

Effect of statin use on atherogenic indices. As shown in Supplementary table 14,
In comparison to statin-free group, the group with statin use exhibited a significant
decrease in levels of AI, CRI-I, CRI-II, and LCI, whereas adjusted AIP, AIP, and
RLP-C did not show a statistically significant difference.

375

376 **DISCUSSION**

In our study, the baseline data analysis revealed that individuals with both HBV and 377 CVD exhibited notably reduced levels of TG and Lp(a) compared to those with CVD 378 379 alone. This observation could potentially be attributed to the varying prevalence of diabetes and the utilization of statins among the patient population. Consequently, it is 380 imperative to stratify the HBV cohort based on their statin and diabetes risk profiles in 381 382 order to comprehensively assess the diverse clinical outcomes in patients with CVD. The utilization of statins has the capacity to diminish the prevalence of CHD and AP 383 among individuals with CVD associated with HBV infection. Stratification analysis, 384 considering the presence of DM, revealed a notably heightened susceptibility to MI, 385 AMI, and HF in patients with HBV infection combined with CVD. These findings 386 imply that CVD patients with HBV infection should judiciously employ statins and 387 388 effectively manage blood glucose levels.

389 HBV infection has the potential to give rise to a range of intrahepatic and extrahepatic

ailments, encompassing acute and chronic hepatitis, cirrhosis, hepatocellular 390 carcinoma, metabolic syndrome, CVD, and renal injury ³⁹⁻⁴¹. The pathogenesis of 391 392 HBV infection is intricate and multifaceted, essentially manifesting as a multisystem disorder. The underestimation of the influence of HBV infection on atherosclerosis 393 has been observed in academic research. Multiple studies have demonstrated that the 394 inflammation triggered by HBV infection serves as a significant contributing factor to 395 the development of atherosclerosis. Conversely, atherosclerosis also exerts subsequent 396 effects on the severity of chronic HBV infection, thereby establishing a detrimental 397 cycle ¹⁷. In patients concomitant HBV and MAFLD decreases the risk of ASCVD 398 when compared with MAFLD alone, which may attribute to antiviral treatment ⁴¹. 399 The findings of present studies ^{17, 41} and our research indicate that the implementation 400 401 of either antiviral therapy or lipid-lowering statin therapy holds the potential to improve liver metabolism or liver injury, consequently reducing the susceptibility to 402 CVD associated with HBV infection. 403

Our study revealed that HBV infection posed a significant risk for AMI in patients 404 with CVD (OR = 2.24, 95% CI: 1.40-3.57; P = 0.001). However, our findings did not 405 indicate a significant association between HBV infection and MI (OR = 1.08, 95%CI: 406 0.69-1.68; P = 0.815). Analysis of baseline data demonstrated that the proportion of 407 AMI in patients with both HBV infection and CVD was 39.1% (106/271), which was 408 significantly higher than the proportion in patients with CVD alone (23.1%) (52/225; 409 P < 0.001). Currently, there is a lack of pertinent research indicating that HBV 410 infection serves as a risk factor for AMI. Furthermore, the underlying physiological 411

and pathological mechanisms by which HBV infection may contribute to an increased
risk of AMI in patients with CVD remain unclear. It is plausible that our findings may
be attributed to potential data bias, as we did not conduct a multivariate regression
analysis. Moreover, a comprehensive epidemiological investigation with larger
sample sizes is necessary to ascertain the risk of HBV infection in relation to AMI.

According to a comprehensive survey of over 90,000 individuals, patients with HBV 417 and DM was found to be associated with significantly reduced risks of MI (aHR =418 0.49; 95% CI: 0.42 to 0.56), ischaemic stroke (aHR = 0.61; 95% CI: 0.56 to 0.67), HF 419 420 (aHR = 0.50; 95% CI: 0.43 to 0.59), and all-cause mortality (aHR = 0.72; 95% CI: 0.70 to 0.75) when compared to DM alone ¹⁴, while the researchers did not provide a 421 specific explanation. Hence, the association between enhanced liver metabolism 422 423 through antiviral therapy in patients with HBV and its potential correlation with MACE, HF, and all-cause mortality remains uncertain. In our study, the findings of 424 risk stratification based on DM indicate that HBV infection is associated with a 425 426 decreased risk of CDH in patients with CVD (OR = 0.32, 95% CI: 0.15-0.68; P = 0.004). However, when HBV infection is combined with DM, it is associated with an 427 increased risk of MI (OR = 2.12, 95% CI: 1.30 – 3.45; P = 0.002), AMI (OR = 5.37, 428 95% CI: 2.91 - 9.92; P < 0.001), and HF (OR = 2.58, 95% CI: 1.32 - 5.04; P = 0.005). 429 These findings indicate that the clinical consequences linked to HBV infection in 430 individuals with DM may have both positive and negative implications, contingent 431 432 upon various confounding variables including the patient's baseline characteristics, antiviral therapy, diabetes management, and statin administration. 433

Furthermore, a comprehensive analysis was conducted on a cohort of 496 patients 434 diagnosed with CVD to examine the variations in clinical and biochemical markers 435 between individuals with CVD and DM and those without DM. Additionally, the 436 impact of HbA1c levels and DM on various clinical outcomes in patients with CVD 437 was investigated. Moreover, the effects of atorvastatin and rosuvastatin on multiple 438 clinical outcomes in individuals with CVD were also examined. The correlation 439 between DM and the extent of CVD has been examined in prior populations ⁴². The 440 investigation revealed that DM is linked to a greater occurrence of cardiogenic shock, 441 more severe stenosis (\geq 70%) segments, and a higher frequency of complications ⁴³. A 442 recent study encompassed a sample of 23,643 individuals who underwent consecutive 443 coronary CT angiography. In comparison to non-DM patients, those with diabetes 444 445 exhibited a heightened prevalence of obstructive CAD, characterized by more pronounced stenosis in both the proximal and middle segments of the coronary 446 arteries ⁴⁴. HbA1c serves as a precise diagnostic marker for diabetes, enabling the 447 448 assessment of average blood sugar levels over a span of 2-3 months, while remaining minimally influenced by acute illnesses. Moreover, it holds the potential to inform 449 treatment decisions. Subjects with HbA1c levels ranging from 5.7% to 6.4% exhibited 450 elevated levels of coronary artery calcium and carotid intima-media thickness 451 compared to subjects with HbA1c levels below 5.7%, suggesting that an increase in 452 HbA1c levels is linked to an augmented burden of coronary and peripheral 453 atherosclerosis in non-diabetic individuals with normal fasting glucose ⁴⁵. A 454 significant correlation was observed between the decrease in HbA1c levels and the 455

reduction in HR for MACE ⁴⁶. The meta-regression analysis further demonstrated that 456 the mitigation of cardiovascular events among adult individuals with DM can be 457 partially attributed to a decrease in HbA1c levels ⁴⁷. Patients diagnosed with T2DM 458 who exhibit inadequate control of their HbA1c levels (ranging from 8% to 8.9% and 459 equal to or greater than 9%) are found to have comparable or elevated mortality risks 460 when compared to patients diagnosed with CVD⁴⁸. Consequently, it is imperative to 461 prioritize achieving optimal HbA1c levels in order to effectively mitigate risks, 462 prevent mortality, and manage complications associated with DM. 463

The results of our study indicate that elevated HbA1c levels and the presence of DM 464 have a significant influence on various clinical outcomes among individuals 465 diagnosed with CVD. Specifically, our findings demonstrate that individuals with DM 466 467 and HbA1c levels \geq 6% are at an increased risk for developing CHD, experiencing MI, AP, and hypertension. Furthermore, our study examined the impact of both 468 atorvastatin and rosuvastatin on various clinical outcomes among individuals 469 diagnosed with CVD. Notably, patients administered rosuvastatin exhibited the 470 greatest susceptibility to CHD and admission to the CCU, accompanied by elevated 471 rates of NYHA classification. Conversely, these individuals experienced a diminished 472 likelihood of developing UAP. 473

The findings of our study suggest an association between statin use and a decreased risk of HBV infection, potentially due to the inhibitory effects of statins on HBV-DNA replication or clearance. It may be prudent to consider reducing or discontinuing statin therapy in patients with HBV infection who exhibit transaminase

levels exceeding three times the upper limit of normal. Hence, it is important to 478 acknowledge the potential for bias in this conclusion. Additionally, the administration 479 480 of anti-HBV therapy to patients with HBV infection could potentially impact the outcome. The quantification of HBV infection in this study was based on HBsAg 481 levels, and while statin use may reduce HBV-DNA levels until they become 482 undetectable, it is unlikely to result in clearance of HBsAg. Multiple studies have 483 documented the potential of statins to decrease the likelihood of advancing to 484 cirrhosis and hepatocellular carcinoma in individuals with HBV infection ⁴⁹⁻⁵⁴. This is 485 486 attributed to the inhibition or eradication of HBV, which is believed to impede the progression to cirrhosis and liver cancer. Klundert et al. ⁵⁴ discovered that statins 487 inhibit the replication of the hepatitis B virus and decrease the viability of hepatoma 488 489 cells by disrupting Rho-GTPases. Our findings align with this consensus. Furthermore, the HBV viral load remains relatively constant in the absence of effective anti-HBV 490 treatment, suggesting that factors other than statins have minimal impact. Therefore, it 491 492 is plausible to infer that the proposition of stating inhibiting or eradicating HBV is likely valid. 493

To delve deeper into the potential mechanisms of statin therapy in CVD patients to improve clinical outcomes, we conducted additional research on the impact of statin therapy on hepatic function, atherosclerotic burden, and systemic inflammation. The importance of FIB-4 and ALBI grade as the non-invasive indicators for liver fibrosis in predicting CVD among patients with liver diseases or DM has been well documented ⁵⁵⁻⁵⁹. Schonmann et al. ⁵⁸ found that individuals with advanced fibrosis

(FIB-4 \geq 2.67) had a significantly higher risk of cardiovascular disease (HR = 1.60, 500 95% CI: 1.27-2.01) compared to those with inconclusive fibrosis (HR = 1.15, 95% CI: 501 1.01-1.31). Chun et al. ⁵⁹ found a significant difference in the cumulative incidence of 502 CVD among groups stratified by FIB-4. The severity of liver fibrosis was found to 503 independently predict the occurrence of CVD in patients with T2DM. Additionally, 504 the study revealed that the utilization of statins may serve as a protective factor (HR =505 0.603) among individuals with T2DM, thereby mitigating the likelihood of 506 developing CVD ⁵⁹. FIB-4 may have utility in the identification of individuals at 507 elevated risk of CVD within the population of patients diagnosed with NAFLD. 508 Conversely, the use of APRI for this purpose is not advised 60. Our findings indicate 509 that FIB-4 may be more effective than ALBI in assessing liver function in patients 510 511 undergoing atorvastatin therapy. This is primarily due to the ability of FIB-4 to accurately monitor patients with severe liver damage, which was notably reduced in 512 those receiving atorvastatin treatment. Prior research has indicated that statins may 513 514 impact the levels of AST and ALT in NAFLD patients, as well as suggested that FIB-4 as a non-invasive test has an ability to predict hepatic fibrosis 61 . 515

More importantly, our study revealed that both Atorvastatin and Rosuvastatin exhibited a dose-dependent reduction in FIB-4 levels among patients with CVD. A notable increase in the number of patients with FIB-4 grade < 1.45 and a decrease in those with FIB-4 grade > 3.25 were observed, particularly atorvastatin administration. Simon and colleagues ⁶² found that the use of statins was linked to a decrease in incident cirrhosis in a dose-dependent manner. Mohanty et al. ⁶³ discovered that statin

use in patients with HCV is correlated with a reduction of over 40% in the risk of cirrhosis. The prevalence of cirrhosis was found to be 8% lower in the group receiving statin treatment compared to the statins-free group ⁶⁴. Furthermore, the use of statins was correlated with a reduced advancement of liver fibrosis and occurrence of hepatocellular carcinoma in a substantial population of Veterans with HCV infection ⁶⁴. The collective findings of these studies ⁶²⁻⁶⁴ and our own research indicate that statins exhibit the most pronounced antifibrotic effects.

CBCIIs is an important predictor of chronic non-infectious inflammatory response, 529 which is associated with the development of various metabolic system disorders such 530 as fibrosis, hypertension, hyperlipidemia, and hyperglycemia ⁶⁵⁻⁶⁷. SIRI and SII are 531 the two important inflammation indicators based on peripheral blood cell count ^{32, 68}. 532 533 Prospective investigations have identified a correlation between elevated levels of white blood cells and their subtypes, such as neutrophils, monocytes, and 534 lymphocytes, with an augmented susceptibility to coronary heart disease and stroke. 535 Neutrophils are capable of releasing a plethora of inflammatory mediators, 536 chemokines, and oxygen free radicals, thereby instigating endothelial cell damage, 537 consequent tissue ischemia, and a pivotal role in the inflammatory response of 538 atherosclerosis ^{32,68,69}. The activation and differentiation of monocytes into lipid-laden 539 macrophages is a critical step in the pathogenesis of atherosclerotic plaques ^{32,68,69}. 540 Consequently, novel systemic inflammatory markers, such as the SII and SIRI, which 541 are derived from neutrophil counts and other parameters, are likely to be correlated 542 with unfavorable cardiovascular outcomes. In our study, contrasting outcomes were 543

observed between SIRI and SII in assessing the impact of statin use in CVD patients. 544 Specifically, our findings demonstrated a decrease in SIRI levels and an increase in 545 SII levels in patients with CVD following statin therapy. Li et al. ⁷⁰ demonstrated that 546 SIRI is a strong predictor of all-cause mortality in CAD patients with low residual 547 inflammatory risk. Numerous studies have indicated that the SII may serve as a 548 potential biomarker for the development of CVD, with elevated levels of SII being 549 linked to an increased risk of CVD 71-73. SII and SIRI have been linked to 550 cardiovascular disease, yet the impact of statin therapy on these indices remains 551 inconclusive. Following statin therapy, SII levels exhibited a significant increase, 552 whereas SIRI levels showed a significant decrease. Consequently, the influence of 553 statin therapy on the systemic inflammatory response in CVD patients remains 554 555 uncertain and warrants further validation in a larger cohort.

Utilizing initial data, our study determined that the utilization of statins resulted in a 556 significant decrease in TC and LDL-C levels. Additionally, we conducted a thorough 557 558 examination of the impact of statin use on atherogenic indices among individuals diagnosed with CVD. Higher values of novel atherogenic indices, including AIP, 559 CRI-I, CRI-II, and LCI, were found to be significantly associated with an increased 560 risk of coronary artery disease (CAD) when compared to lower values ³⁵. Many 561 investigations indicate that the AIP serves as a novel marker in the contemporary 562 landscape of CVD, with elevated AIP emerging as an independent prognostic factor in 563 patients with CAD ⁷⁴⁻⁷⁷. AI was independently associated with all-cause and CVD 564 mortality among patients undergoing peritoneal dialysis ³⁷. Following adjustments for 565

potential confounders, the highest of AI value exhibited a notably increased hazard 566 ratio for both all-cause mortality and CVD mortality when compared to the lowest AI 567 value ³⁷. Hence, the majority of atherogenicity indicators hold significant implications 568 for the diagnosis and prognosis of CVD risk events. Currently, there is a lack of 569 relevant literature examining the relationship between statin use and atherogenicity 570 indicators. Our research indicates that the use of statins has a significant impact on 571 reducing levels of AI, CRI-I, CRI-II, and LCI. These findings suggest that statins may 572 573 have a positive effect on liver fibrosis by improving lipid metabolism. Additionally, 574 atherogenic indices such as AI, CRI-I, CRI-II, and LCI could serve as valuable markers for assessing liver fibrosis in patients undergoing statin therapy for CVD. 575 It is important to acknowledge that our study has several limitations. Firstly, the 576

577 recruitment of patients was limited to a single center, and the sample size was moderate. Secondly, there is a dearth of information pertaining to the duration of 578 hyperlipidemia, hypertension, and diabetes. Consequently, when assessing the impact 579 580 of diabetes and its complications, it is not possible to disregard the potential influence of unmeasured confounding factors. Thirdly, the measurement of HbA1c may be 581 susceptible to interference from hemoglobin variants, hereditary hemoglobinopathies, 582 thalassemia, and iron-deficiency anemia. However, HbA1c serves as a reliable 583 indicator of prolonged blood glucose regulation and exhibits reduced inter-individual 584 variability in contrast to impaired glucose tolerance and fasting plasma glucose. 585 Moreover, it is crucial to acknowledge that our analysis solely encompasses a single 586 measurement of HbA1c, thereby rendering the alterations in glycemic control 587

588 parameters indeterminate. Furthermore, this investigation solely encompasses 589 inpatient data, precluding the assessment of long-term follow-up. Consequently, it is 590 advisable to employ more sophisticated methodologies, such as cohort studies, to 591 further investigate this matter.

592 CONCLUSION

Our study indicates that CVD patients who also have HBV infection may experience 593 a reduction in MACEs when treated with statins. DM with an HBA1c level of ≥ 6 is 594 identified as risk factor for the development of CHD, MI, AP, and hypertension. The 595 596 implementation of statins has demonstrated the potential to reduce the incidence of CHD and AP in individuals with CVD. The analysis of stratification, taking into 597 account the presence of DM, has demonstrated a significantly increased vulnerability 598 599 to MI, AMI, and HF among individuals with HBV infection combined with CVD. Furthermore, our findings reveal that long-term glycemic control should be prioritized 600 in this patient population. Our findings also indicate that FIB-4 could serve as a 601 602 potential indicator for assessing liver function in individuals undergoing treatment with statins. Statin therapy resulted in reduction in TC and LDL-C levels, as well as 603 improvement of atherogenicity markers such as AI, CRI-I, CRI-II, and LCI. The 604 results of our study indicate that statins may potentially ameliorate liver fibrosis 605 through enhancement of lipid metabolism. Furthermore, atherogenic indices including 606 AI, CRI-I, CRI-II, and LCI may serve as useful indicators for evaluating liver fibrosis 607 in individuals receiving statin treatment for CVD. The observed improvements in 608 hepatic function, atherosclerotic burden, and systemic inflammation associated with 609

- statin therapy may contribute to the favorable outcomes among individuals with CVD.
- 611

612 Sources of Funding

- 613 This work received financial support from the Natural Science Foundation of Shaanxi
- 614 Province, China (Grant No. 2022SF-243).
- 615 **Disclosures**
- 616 Prof. Wang received grants from the Natural Science Foundation of Shaanxi Province,
- 617 China. The authors declare that they have no competing interests.
- 618 Supporting information
- 619 Table S1-Table S14.

REFERENCES 620

- Global, regional, and national age-sex-specific mortality for 282 causes of 1. 621 death in 195 countries and territories, 1980-2017: A systematic analysis for the 622
- global burden of disease study 2017. Lancet (London, 623 England).
- 2018;392:1736-1788. doi: 10.1016/S0140-6736 (18) 32203-7. 624
- 2. Stone PH, Libby P, Boden WE. Fundamental pathobiology of coronary 625 atherosclerosis and clinical implications for chronic ischemic heart disease 626
- management-the plaque hypothesis: A narrative review. JAMA cardiology. 627
- 628 2023;8:192-201. doi: 10.1001/jamacardio.2022.3926.
- 3. Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clinical chemistry. 629 2021;67:154-166. doi: 10.1093/clinchem/hvaa247. 630
- 631 4. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: Jacc health promotion series. Journal of the American 632 College of Cardiology. 2018;72:1141-1156. doi: 10.1016/j.jacc.2018.06.046. 633
- 5. 634 Vujkovic M, Keaton JM, Lynch JA, Assimes TL, Chang KM, Cho K, Lee JS,
- Gaziano JM, Phillips LS, Damrauer SM, DuVall SL, Gao L, Kaestner KH,
- Susztak K. Discovery of 318 new risk loci for type 2 diabetes and related 636 vascular outcomes among 1.4 million participants in a multi-ancestry 637 meta-analysis. Nature genetics. 2020;52:680-691. doi: 638
- 10.1038/s41588-020-0637-y. 639

635

Clarke R, Von Ende A, Hill M, Hopewell JC, Hughes AD, Mayr M, Pechlaner 6. 640 R, Schmidt LE, Theofilatos K, Watkins H, Watkins H, Yin X. Apolipoprotein 641

642	proteomics for residual lipid-related risk in coronary heart disease. Circulation
643	research. 2023;132:452-464. doi: 10.1161/CIRCRESAHA.122.321690.

- 644 7. Huang Y, Ren Y, Yang H, Ding Y, Liu Y, Yang Y, Mao A, Yang T, Wang Y,
- 545 Xiao F, He Q, Zhang Y. Using a machine learning-based risk prediction model
- to analyze the coronary artery calcification score and predict coronary heart
- 647 disease and risk assessment. *Computers in biology and medicine*.
- 648 2022;151:106297. doi: 10.1016/j.compbiomed.2022.106297.
- 649 8. Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw
- 650 LJ, Blankstein R, Miedema MD, Berman DS, Budoff MJ, Krumholz HM,
- 651 Blaha MJ, Nasir K. Interplay of coronary artery calcium and risk factors for
- predicting cvd/chd mortality: The cac consortium. JACC. Cardiovascular *imaging*. 2020;13:1175-1186. doi: 10.1016/j.jcmg.2019.08.024.
- Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and
 cardiovascular disease: An update. *Nature reviews. Cardiology*.
 2010;7:369-375. doi: 10.1038/nrcardio.2010.35.
- Nauta ST, Deckers JW, Akkerhuis KM, van Domburg RT. Short- and
 long-term mortality after myocardial infarction in patients with and without
 diabetes: Changes from 1985 to 2008. *Diabetes care*. 2012;35:2043-2047. doi:
 10.2337/dc11-2462
- 11. Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis b virus (hbv)
 infection. *Journal of medical virology*. 2015;87:1989-1999. doi:
 10.1002/jmv.24270.

- Cacoub P, Asselah T. Hepatitis b virus infection and extra-hepatic
 manifestations: A systemic disease. *The American journal of gastroenterology*.
- 666 2022;117:253-263. doi: 10.14309/ajg.00000000001575.
- 13. Hamilton EM, Yang L, Avery D. Chronic hepatitis b virus infection and risk of
- stroke types: A prospective cohort study of 500 000 chinese adults. *Stroke*.

669 2023;54:3046-3053. doi: 10.1161/STROKEAHA.123.043327.

- 14. Kuo CS, Chen YT, Hsu CY, Chang CC, Chou RH, Li SY, Kuo SC, Huang PH,
- 671 Chen JW, Lin SJ. The impact of chronic hepatitis b infection on major adverse
- 672 cardiovascular events and all-cause mortality in patients with diabetes: A
- nationwide population-based study from taiwan. *BMJ open.* 2017;7:e016179.
- doi: 10.1136/bmjopen-2017-016179.
- Ke ZP, Gong M, Zhao G, Geng Y, Cheng K. Association between hbv
 infection and the prevalence of coronary artery disease in the us population.
- 677 *Computational and mathematical methods in medicine*. 2022;2022:5062798.
- 678 doi: 10.1155/2022/5062798.
- Kumar A, Shariff M, Doshi R. Association between past hepatitis b infection
 and ischemic heart disease: An analysis from the 2007-2016 nhanes data. *The American journal of the medical sciences*. 2020;360:372-377. doi:
 10.1016/j.amjms.2020.05.034.
- Ranković I, Milivojević V, Pavlović Marković A, Bezmarević M. Interplay
 between chronic hepatitis b and atherosclerosis: Innovative perspectives and
 theories. *World journal of gastroenterology*. 2022;28:497-499. doi:

686 10.3748/wjg.v28.i4.497.

687	18.	Wu VC, Chen TH, Wu M, Cheng	CW, Chen SW, Chang CW, Chen CC, Chan	۱g
688		SH, Hung KC, Chern MS, Li	in FC, Chu PH, Wu CS. Comparison	of
689		cardiovascular outcomes and al	ll-cause mortality in patients with chron	ic
690		hepatitis b and c: A 13-year i	nationwide population-based study in asi	a.
691		Atherosclerosis.	2018;269:178-184. do	oi:
692		10.1016/j.atherosclerosis.2018.01	.007.	

- 693 19. Kim D, Adejumo AC, Yoo ER, Iqbal U, Li AA, Pham EA, Cholankeril G,
- Glenn JS, Ahmed A. Trends in mortality from extrahepatic complications in
 patients with chronic liver disease, from 2007 through 2017. *Gastroenterology*.
 2019;157:1055-1066.e1011. doi: 10.1053/j.gastro.2019.06.026.
- Liu XY, Zhou Y. Influence of hepatitis b virus on the prevalence of diabetes
 complications in patients with type 2 diabetes. *Journal of diabetes investigation*. 2023;14:429-434. doi: 10.1111/jdi.13954.
- 700 21. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn
- EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED,
- 702 Miedema MD, Muñoz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J,
- Ziaeian B. 2019 acc/aha guideline on the primary prevention of cardiovascular
 disease: A report of the american college of cardiology/american heart
 association task force on clinical practice guidelines. *Circulation*.
 2019;140:e596-e646. doi: 10.1161/CIR.00000000000678.
- 22. Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, Sun D, Tan L, Mu L, Liu J, Feng

- F, Yang H, Zhao H, Schulz WL, Krumholz HM, Pan X, Li J. Prevalence of
 dyslipidemia and availability of lipid-lowering medications among primary
- health care settings in china. JAMA network open. 2021;4:e2127573. doi:
- 711 10.1001/jamanetworkopen.2021.27573.
- Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and
 management of cirrhosis, portal hypertension, and hcc. *Hepatology (Baltimore, Md.*). 2023;78:1896-1906. doi: 10.1097/HEP.00000000000278.
- 715 24. Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, Cha BS, Choi JY, Lee
- YH. Ezetimibe combination therapy with statin for non-alcoholic fatty liver
 disease: An open-label randomized controlled trial (essential study). *BMC medicine*. 2022;20:93. doi: 10.1186/s12916-022-02288-2.
- 719 25. Shaffer LR, Mahmud N. Statins in cirrhosis: Hope or hype? *Journal of clinical*720 *and experimental hepatology*. 2023;13:1032-1046. doi:
 724 10.1016/j.iceb.2022.05.002
- 721 10.1016/j.jceh.2023.05.002.
- 722 26. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V,
- 723 Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D,
- Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L.
- Statin use and non-alcoholic steatohepatitis in at risk individuals. *Journal of hepatology*. 2015;63:705-712. doi: 10.1016/j.jhep.2015.05.006.
- 727 27. Tessier CM, Polyzos SA, Athyros VG, Mantzoros CS. Long-term statin
 728 treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease:
 729 Is it time to give the emperor a statin robe? *Metabolism: clinical and*

experimental. 2021;121:154796. doi: 10.1016/j.metabol.2021.154796. 730

- 28. Boutari C, Pappas PD, Anastasilakis D, Mantzoros CS. Statins' efficacy in 731 732 non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinical nutrition (Edinburgh, Scotland). 2022;41:2195-2206. 733 doi: 10.1016/j.clnu.2022.08.001. 734
- Navarro P, Gutiérrez-Ramírez L, Arias Á, Lucendo AJ, Tejera-Muñoz A. 29. 735 Systematic review and meta-analysis: Prevalence of non-alcoholic fatty liver 736 disease and liver fibrosis in patients with inflammatory bowel disease. 737 738 Nutrients. 2023;15:4507. doi: 10.3390/nu15214507.
- 30. Martínez-Domínguez SJ, García-Mateo S, Laredo V, Gargallo-Puyuelo CJ, 739 Gallego Llera B, López de la Cruz J, Gomollón F. Liver fibrosis in 740 741 non-alcoholic fatty liver disease and progression to hepatocellular carcinoma in patients with inflammatory bowel disease: A systematic review. Cancers. 742 2023;15:3367. doi: 10.3390/cancers15133367. 743
- Tian YB, Niu H, Xu F, Shang-Guan PW, Song WW. Albi score combined with 744 31. fib-4 index to predict post-hepatectomy liver failure in patients with 745 hepatocellular carcinoma. Scientific 2024;14:8034. 746 reports.

doi:

- 10.1038/s41598-024-58205-5. 747
- Li J, He D, Yu J, Chen S, Wu Q, Cheng Z, Wei Q, Xu Y, Zhu Y, Wu S. 748 32. Dynamic status of sii and siri alters the risk of cardiovascular diseases: 749 Evidence from kailuan cohort study. Journal of inflammation research. 750 2022;15:5945-5957. doi: 10.2147/JIR.S378309. 751

752	33.	Xiu J, Lin X, Chen Q, Yu P, Lu J, Yang Y, Chen W, Bao K, Wang J, Zhu J,
753		Zhang X, Pan Y, Tu J, Chen K, Chen L. The aggregate index of systemic
754		inflammation (aisi): A novel predictor for hypertension. Frontiers in
755		cardiovascular medicine. 2023;10:1163900. doi: 10.3389/fcvm.2023.1163900.
756	34.	Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: Pathophysiology
757		and the role of calculated lipid indices in assessing cardiovascular risk in
758		patients with hyperlipidemia. International journal of molecular sciences.
759		2022;24:75. doi: 10.3390/ijms24010075.
760	35.	Mahdavi-Roshan M, Mozafarihashjin M, Shoaibinobarian N, Ghorbani Z,
761		Salari A, Savarrakhsh A, Hekmatdoost A. Evaluating the use of novel
762		atherogenicity indices and insulin resistance surrogate markers in predicting
763		the risk of coronary artery disease: A case-control investigation with
764		comparison to traditional biomarkers. Lipids in health and disease.
765		2022;21:126. doi: 10.1186/s12944-022-01732-9.
766	36.	Vargas HO, Nunes SO, Barbosa DS, Vargas MM, Cestari A, Dodd S,
767		Venugopal K, Maes M, Berk M, Castelli risk indexes 1 and 2 are higher in

- gol ٠, g major depression but other characteristics of the metabolic syndrome are not 768 specific to mood disorders. Life sciences. 2014;102:65-71. doi: 769 10.1016/j.lfs.2014.02.033. 770
- 37. Deng J, Tang X, Tang R, Chen J, Guo H, Zhou Q, Zhan X, Long H, Peng F,
 Wang X, Wen Y, Feng X, Su N, Tian N, Wu X, Xu Q. Atherogenic index
 predicts all-cause and cardiovascular mortality in incident peritoneal dialysis

- 774
 patients.
 Atherosclerosis.
 2023;387:117389.
 doi:

 775
 10.1016/j.atherosclerosis.2023.117389.
- Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the
 cardiovascular system. *Circulation research*. 2017;120:229-243. doi:
 10.1161/CIRCRESAHA.116.308537.
- 779 39. Tian T, Song C, Jiang L, Dai J, Lin Y, Xu X, Yu C, Ge Z, Ding Y, Wen Y, Liu
- B, Shao Y, Shi P, Zhu C, Liu Y, Jing S, Wang Z, Hu Z, Li J. Hepatitis b virus
 infection and the risk of cancer among the chinese population. *International journal of cancer*. 2020;147:3075-3084. doi: 10.1002/ijc.33130.
- 40. Motamed-Gorji N, Eghtesad S, Sharafkhah M, Masoudi S, Darvishian M,
- 784 Eslami L, Gharavi A, Khoshnia M, Roshandel G, Shayanrad A, Hariri S,
- Merat S, Poustchi H, Malekzadeh R. All-cause and cause-specific mortality in
 middle-aged individuals with positive hbsag: Findings from a prospective
 cohort study. *Archives of Iranian medicine*. 2022;25:139-147. doi:
 10.34172/aim.2022.24.
- Cheng YM, Hsieh TH, Wang CC, Kao JH. Impact of hbv infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease. *JHEP reports : innovation in hepatology*. 2023;5:100836. doi:
- 792 10.1016/j.jhepr.2023.100836.
- Khawaja T, Linge J, Leinhard OD, Al-Kindi SG, Rajagopalan S, Khera A, de
 Lemos JA, Joshi P, Neeland IJ. Coronary artery calcium, hepatic steatosis, and
 atherosclerotic cardiovascular disease risk in patients with type 2 diabetes

796	mellitus:	Results	from 1	the da	allas	heart	study.	Progress	in car	diovas	cular
797	diseases.	2023;78	8:67-73.	. doi:	10.1	016/j.j	pcad.20	023.03.002	. Epub	2023	Mar
798	15.										

- Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F,
 Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW,
 Marco J, Gitt AK. Impact of diabetes mellitus status on coronary
 pathoanatomy and interventional treatment: Insights from the euro heart
 survey pci registry. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*.
 2011;78:702-709. doi: 10.1002/ccd.22939.
- 806 44. Rana JS, Dunning A, Achenbach S, Al-Mallah M, Budoff MJ, Cademartiri F,
- 807 Callister TQ, Chang HJ, Cheng VY, Chinnaiyan K, Chow BJ, Cury R, Delago A, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufmann P, Karlsberg RP, Kim 808 YJ, Leipsic J, Labounty TM, Lin FY, Maffei E, Raff G, Villines TC, Shaw LJ, 809 810 Berman DS, Min JK. Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes 811 undergoing coronary computed tomography angiography: Results from 10,110 812 individuals from the confirm (coronary ct angiography evaluation for clinical 813 814 outcomes): An international multicenter registry. **Diabetes** care. 2012;35:1787-1794. doi: 10.2337/dc11-2403. 815
- 816 45. Scicali R, Giral P, Gallo A, Di Pino A, Rabuazzo AM, Purrello F, Cluzel P,
 817 Redheuil A, Bruckert E, Rosenbaum D. Hba1c increase is associated with

818 higher coronary and peripheral atherosclerotic burden in non diabetic patients	818	higher coronary and peripheral atherosclerotic burden in non diabetic patients
--	-----	--

- 819 *Atherosclerosis.* 2016;255:102-108. doi:
- 820 10.1016/j.atherosclerosis.2016.11.003.
- 46. Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K,
- Giugliano D. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: An updated meta-regression. *Cardiovascular diabetology*. 2021;20:210. doi:
- 825 10.1186/s12933-021-01401-8.
- 47. Fralick M, Colacci M, Odutayo A, Siemieniuk R, Glynn RJ. Lowering of
 hemoglobin a1c and risk of cardiovascular outcomes and all-cause mortality, a
 meta-regression analysis. *Journal of diabetes and its complications*.
 2020;34:107704. doi: 10.1016/j.jdjacomp.2020.107704.
- 830 48. Wan EYF, Yu EYT, Mak IL, Youn HM, Chan KS, Chan EWY, Wong ICK,
- Lam CLK. Diabetes with poor-control hba1c is cardiovascular disease 'risk equivalent' for mortality: Uk biobank and hong kong population-based cohort study. *BMJ open diabetes research & care*. 2023;11. doi:
- 834 10.1136/bmjdrc-2022-003075.
- 49. Vell MS, Loomba R, Krishnan A, Wangensteen KJ, Trebicka J, Creasy KT,
- Trautwein C, Scorletti E, Seeling KS, Hehl L, Rendel MD, Zandvakili I, Li T,
- 837 Chen J, Vujkovic M, Alqahtani S, Rader DJ, Schneider KM, Schneider CV.
- Association of statin use with risk of liver disease, hepatocellular carcinoma,
- and liver-related mortality. JAMA network open. 2023;6:e2320222. doi:

840 10.1001/jamanetworkopen.2023.20222.

- 50. Yun B, Ahn SH, Yoon JH, Kim BK. Statin use and risk of progression to liver
 cirrhosis in chronic hepatitis b independent of conventional risk factors: A
 nationwide study. *Hepatology communications*. 2022;6:2455-2464. doi:
 10.1002/hep4.2022.
- Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the
 risk of hepatocellular carcinoma and death in a hospital-based hepatitis
 b-infected population: A propensity score landmark analysis. *Journal of hepatology*. 2015;63:1190-1197. doi: 10.1016/j.jhep.2015.07.009.
- Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are asso
 -ciated with a reduced risk of hepatocellular cancer: A systematic review
 and meta-analysis. *Gastroenterology*. 2013;144:323-332. doi: 10.1053/j.gas
- tro.2012.10.005.
- Solution Schwarz Schw
- van de Klundert M, Ringelhan M, Protzer U. Statins suppress hepatitis b virus
 replication and reduce hepatoma cell viability by interfering with rho-gtpases. *Journal of hepatology*. 2018;68:S782. doi: 10.1016/S0168-8278(18)31833-6
- 860 55. Guan L, Li L, Zou Y, Zhong J, Qiu L. Association between fib-4, all-cause
 861 mortality, cardiovascular mortality, and cardiovascular disease risk among

- diabetic individuals: Nhanes 1999-2008. *Frontiers in cardiovascular medicine*.
- 863 2023;10:1172178. doi: 10.3389/fcvm.2023.1172178.
- 864 56. Seo YG, Polyzos SA, Park KH, Mantzoros CS. Fibrosis-4 index predicts
- 865 long-term all-cause, cardiovascular and liver-related mortality in the adult
- korean population. Clinical gastroenterology and hepatology : the official
- 867 clinical practice journal of the American Gastroenterological Association.

868 2023;21:3322-3335. doi: 10.1016/j.cgh.2023.04.026.

- 869 57. Roca-Fernandez A, Banerjee R, Thomaides-Brears H, Telford A, Sanyal A,
- 870 Neubauer S, Nichols TE, Raman B, McCracken C, Petersen SE, Ntusi NA,
- 871 Cuthbertson DJ, Lai M, Dennis A, Banerjee A. Liver disease is a significant
- risk factor for cardiovascular outcomes a uk biobank study. *Journal of hepatology*. 2023;79:1085-1095. doi: 10.1016/j.jhep.2023.05.046.
- 58. Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an
- independent predictor of cardiovascular morbidity and mortality in the general
- 876 population. *Digestive and liver disease : official journal of the Italian Society*
- 877 of Gastroenterology and the Italian Association for the Study of the Liver.

878 2021;53:79-85. doi: 10.1016/j.dld.2020.10.014. Epub 2020 Nov 2.

59. Chun HS, Lee JS, Kim BK, Lee HW, Lee YH, Kim YD, Kim SU, Park JY,
Kim DY, Ahn SH. Association between the severity of liver fibrosis and
cardiovascular outcomes in patients with type 2 diabetes. *Journal of gastroenterology and hepatology*. 2021;36:1703-1713. doi:
10.1111/jgh.15387.

884 60. Yi M, Peng W, Teng F, Kong Q, Chen Z. The role of noninvasive scoring
885 systems for predicting cardiovascular disease risk in patients with
886 nonalcoholic fatty liver disease: A systematic review and meta-analysis.
887 *European journal of gastroenterology & hepatology*. 2022;34:1277-1284. doi:

- 888 10.1097/MEG.00000000002462.
- Al-Karaghouli M, Fuentes S, Davyduke T, Ma M, Abraldes JG. Impact of
 statin treatment on non-invasive tests based predictions of fibrosis in a referral
 pathway for nafld. *BMJ open gastroenterology*. 2022;9:e000798. doi:
 10.1136/bmjgast-2021-000798.
- 893 62. Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin
 894 are associated with dose-dependent reductions in cirrhosis and hepatocellular
 895 carcinoma, among patients with hepatitis c virus: Results from erchives.
 896 *Hepatology (Baltimore, Md.).* 2016;64:47-57. doi: 10.1002/hep.28506.
- Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased
 risk of decompensation and death in veterans with hepatitis c-related
 compensated cirrhosis. *Gastroenterology*. 2016;150:430-440.e431.doi:
 10.1053/j.gastro.2015.10.007.
- 901 64. Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung
- 902 RT, Rogal SS. Effect of addition of statins to antiviral therapy in hepatitis c
 903 virus-infected persons: Results from erchives. *Hepatology (Baltimore, Md.)*.
 904 2015;62:365-374. doi: 10.1002/hep.27835.
- 905 65. Yousaf H, Khan MIU, Ali I, Munir MU, Lee KY. Emerging role of

906		macrophages in non-infectious diseases: An update. Biomedicine &
907		<i>pharmacotherapy = Biomedecine & pharmacotherapie</i> . 2023;161:114426.doi:
908		10.1016/j.biopha.2023.114426.
909	66.	Cho S, Ying F, Sweeney G. Sterile inflammation and the nlrp3 inflammasome
910		in cardiometabolic disease. Biomedical journal. 2023;46:100624. doi:
911		10.1016/j.bj.2023.100624.
912	67.	Zinellu A, Paliogiannis P. Blood cell count derived inflammation indexes in
913		patients with idiopathic pulmonary fibrosis. Lung. 2020;198:821-827. doi:
914		10.1007/s00408-020-00386-7.

- 68. Kong F, Huang J, Xu C, Huang T, Wen G, Cheng W. System inflammation
 response index: A novel inflammatory indicator to predict all-cause and
 cardiovascular disease mortality in the obese population. *Diabetology & metabolic syndrome*. 2023;15:195. doi: 10.1186/s13098-023-01178-8.
- 919 69. Wang P, Guo X, Zhou Y, Li Z, Yu S, Sun Y, Hua Y. Monocyte-to-high-density
 920 lipoprotein ratio and systemic inflammation response index are associated
 921 with the risk of metabolic disorders and cardiovascular diseases in general
 922 rural population. *Frontiers in endocrinology*. 2022;13:944991. doi:
 923 10.3389/fendo.2022.944991.
- 924 70. Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, Wang Z, Feng Y, Wang Q,
- Guo X, Tang X, Xu J, Song Y, Chen Y, Xu N, Yao Y, Liu R, Zhu P, Han Y,
 Yuan J. Prognostic significance of inflammation in patients with coronary

927

artery disease at low residual inflammatory risk. iScience. 2023;26:108060.

928 doi: 10.1016/j.isci.2023.108060.

- 929 71. Ye Z, Hu T, Wang J, Xiao R, Liao X, Liu M, Sun Z. Systemic
 930 immune-inflammation index as a potential biomarker of cardiovascular
 931 diseases: A systematic review and meta-analysis. *Frontiers in cardiovascular*932 *medicine*. 2022;9:933913. doi: 10.3389/fcvm.2022.933913.
- 933 72. Ma J, Li K. Systemic immune-inflammation index is associated with coronary
 934 heart disease: A cross-sectional study of nhanes 2009-2018. *Frontiers in*
- 935 *cardiovascular medicine*. 2023;10:1199433. doi: 10.3389/fcvm.2023.1199433.
- 73. Zhao Z, Zhang X, Sun T, Huang X, Ma M, Yang S, Zhou Y. Prognostic value
 of systemic immune-inflammation index in cad patients: Systematic review
 and meta-analyses. *European journal of clinical investigation*.
 2024;54:e14100. doi: 10.1111/eci.14100.
- 74. Rabiee Rad M, Ghasempour Dabaghi G, Darouei B, Amani-Beni R. The
 association of atherogenic index of plasma with cardiovascular outcomes in
 patients with coronary artery disease: a systematic review and meta-analysis.
- 943 *Cardiovascular diabetology*. 2024;23:119. doi: 10.1186/s12933-024-02198-y.
- 944 75. Min Q, Wu Z, Yao J, Wang S, Duan L, Liu S, Zhang M, Luo Y, Ye D, Huang Y,
- Chen L, Xu K, Zhou J. Association between atherogenic index of plasma
 control level and incident cardiovascular disease in middle-aged and elderly
 chinese individuals with abnormal glucose metabolism. *Cardiovascular diabetology*. 2024;23:54. doi: 10.1186/s12933-024-02144-y.
- 949 76. Wang Y, Wang S, Sun S, Li F, Zhao W, Yang H, Wu X. The predictive value of

950	atherogenic index of plasma for cardiovascular outcomes in patients with
951	acute coronary syndrome undergoing percutaneous coronary intervention with
952	ldl-c below 1.8mmol/l. Cardiovascular diabetology. 2023;22:150. doi:
953	10.1186/s12933-023-01888-3.

- 954 77. Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA,
 955 Pérez-Maldonado IN. Atherogenic index of plasma: Novel predictive
 956 biomarker for cardiovascular illnesses. *Archives of medical research*.
 957 2019;50:285-294. doi: 10.1016/j.arcmed.2019.08.009.
- 958

959 Figure legends

Figure 1 Flow diagram of cohort selection. Consequently, a final sample size of 496 participants was included in the study. The patients were categorized into two groups according to their surface antigen status: patients with coexisting CVD and HBV (n =225) and patients with CVD alone (n = 271). CVD, cardiovascular disease; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.

Figure 2 The impact of HBV infection, stratified by statins use, on multiple clinical
outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI,
myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary
care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart
failure.

Figure 3 The impact of HBV infection, stratified by DM, on multiple clinical
outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI,

972	myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary
973	care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart
974	failure.

- 975 Figure 4 The impact of DM, stratified by statins use, on multiple clinical outcomes
- among CVD patients. OR, odds ratio; CDH, coronary heart disease; MI, myocardial
- 977 infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary care unit; AMI,
- acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure.
- **Figure 5** The impact of HbA1c ($\geq 6\%$ or < 6%), stratified by stating use, on multiple
- 980 clinical outcomes among CVD patients. OR, odds ratio; CDH, coronary heart disease;
- 981 MI, myocardial infarction; AP, angina pectoris; DM, diabetes mellitus; CCU, coronary
- 982 care unit; AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart
- 983 failure.



Characteristics	Total (N)	OR (95% CI)		P value
CDH	427		I	0.001
no	39	Reference		
yes	388	0.27 (0.12 - 0.60)	● • 1	0.015
IVII	4 <i>21</i> 27 <i>4</i>	Reference		0.015
	153			
AP	427	1.00 (0.00 1.00)	Ĭ	0.008
no	119	Reference	I	01000
yes	308	0.56 (0.36 - 0.86)	- ↓	
Hypertension (extreme risk)	427			0.436
no	256	Reference		
yes	1/1	0.82 (0.53 - 1.27)	i∎ I	0 126
	427 299	Reference	i	0.150
Ves	128	0.68(0.42 - 1.09)		
ŬĴĴ	427		Ĩ	0.611
no	331	Reference	I	
yes	96_	1.17 (0.71 - 1.94)		
AMI	427			0.001
no	296		I. A .	
	131	2.24 (1.40 - 3.57)	,	0 953
no	86	Reference	I	0.300
Ves	341	0.84(0.52 - 1.36)	· •	
HF	427			0.304
no	351	Reference	1	
yes	76	1.50 (0.91 - 2.50)	• ` • ♦ − −•	
NYHA classification	427	Defenses	I	0.436
	98		<u>.</u>	
Killin classification	329 427	0.07(0.42 - 1.00)	· ↓ ĩ	0 939
Class I	417	Reference		0.000
≥ Class II	10	2.05 (0.52 - 8.03)		
Secondary clinical outcome	427			0.17
no	74	Reference	i ,	
, yes	353	1.53 (0.88 - 2.66)	т ◆ − ⊣	0.004
Primary clinical outcome	427	Deference	I	0.624
	368	0.97 (0.56 - 1.69)		
yco	000	0.07 (0.00 - 1.00)		
			0 1 2 3 4 5	

Characteristics	Total (N)	OR (95% CI)	P value
CDH	496		0.004
no	45	Reference	. 1
yes	451	0.32 (0.15 - 0.68)	♦.
MI (non-DM)	223	5 (0.384
no	164	Reference	ام
yes	59	0.76 (0.42 - 1.40)	T
MI (DM)	2/3		ı 0.002
no	154	Reference	
yes	119	2.12 (1.30 - 3.45)	
AP	490	Deference	I 0.084
10 V22	137		
yes Hypertonoion (extreme rick)	309	0.68 (0.45 - 1.03)	
hypertension (extreme hsk)	490	Deference	0.020
	299	$\begin{array}{c} Reletence \\ 0 0 4 (0 65 \ 1 27) \end{array}$	
yes CCU	197	0.94(0.05 - 1.37)	0.407
	306	Poforonco	0.497
	100	1 20 (0 77 1 87)	
AMI (non-DM)	223	1.20 (0.77 - 1.07)	0.396
	138	Reference	I
	85	0.79(0.45 - 1.37)	4 .
	273	0.75 (0.45 1.07)	1 < 0.001
no	200	Reference	1
Ves	73	5 37 (2 91 - 9 92)	' ⊢ – ♠ – – – –
UAP	496	0.07 (2.01 0.02)	0.412
no	99	Reference	0.112
Ves	397	0.81(0.51 - 1.27)	
HF (non-DM)	223		0.519
no	175	Reference	
Ves	48	0.81 (0.42 - 1.55)	•
HF'(DM)	273		0.005
no	227	Reference	I
ves	46	2.58 (1.32 - 5.04)	⊢ ♦ − ⊣
NYHA classification	496	,	ı 0.468
Class I	108	Reference	I
≥ Class II	388	0.83 (0.54 - 1.28)	•
Killip classification	496		0.243
Class I	485	Reference	
≥ Class II	11	2.25 (0.59 - 8.59)	
Secondary clinical outcome (non-DM)	223		0.981
no	37	Reference	
yes	186	1.01 (0.49 - 2.09)	
Secondary clinical outcome (DM)	2/3		< 0.001
no	4/	Reference	
yes Deire on a clinical automatic	226	4.34 (2.06 - 9.15)	
Primary clinical outcome	496	Defenses	ı U.847
no	CO 4 2 4		▲.
yes	431	0.91 (0.03 - 1.00)	
			0.0 2.5 5.0 7.5 10.0

Characteristics	Total (N)	OR (95% CI)		P value
CDH	494		I I	< 0.001
no	44	Reference	I	
yes	450	6.9 (3.2 - 14.9)	Ⅰ	
MI	494			< 0.001
no	316	Reference		
yes	178	2.2 (1.5 - 3.2)	i •	
AP (no statins use)	79		Î	0.01
no	34	Reference	I	
yes	45	3.5 (1.3 - 9.3)		
AP (atorvastatin 20 mg)	225			0.063
no	51	Reference		
yes	174	1.8 (1.0 - 3.4)	♦	
AP (rosuvastatin 10 mg)	190	, , , , , , , , , , , , , , , , , , ,	I.	0.669
no	51	Reference	I	
ves	139	0.87 (0.46 - 1.65)	•	
Hypertension (extreme risk)	494	, ,	1	< 0.001
no	297	Reference		
Ves	197	2.9(2.0 - 4.2)	I ⊨ ♦ −1	
ĊĊŬ	494		I.	0.554
no	394	Reference	I	
Ves	100	1.2 (0.7 - 1.9)	•	
ÂMI	494			0.006
no	337	Reference	i	0.000
Ves	157	0.57 (0.39 - 0.84)	♦	
UAP	494		Ĩ	0.059
no	99	Reference		
Ves	395	0.63(0.39 - 0.99)		
HF	494			0 166
no	403	Reference	i	0.100
Ves	93	0.70(0.45 - 1.11)		
NYHA classification	494		Ĩ	0 879
Class I	108	Reference		01070
≥ Class II	386	11(07 - 16)	•	
Killin classification	494		Ĭ	0 195
Class I	483	Reference	I	0.100
> Class II	11	33(07 - 157)	! - 	
Secondary clinical outcome	494			0 787
no	84	Reference		0.101
Ves	410	0.91(0.57 - 1.46)	• •	
Primary clinical outcome	494		Ĭ	0 208
nn	65	Reference	I	0.200
VAS	429	0.68 (0.40 - 1.17)	▲	
,			0 5 10 15	

Characteristics	Total (N)	OR (95% CI)		P value
CDH (no statins use)	76			< 0.001
no	14	Reference		
yes	62	34.4 (4.2 - 283.6)	· ◆	*
CDH (atorvastatin 20 mg)	218	Defenses	I	0.085
no	19	Reference	k	
yes	199	2.3 (0.9 - 5.9)	*	1
CDH (rosuvasialin 10 mg)	180	Deference	I	I
10	0		L .	
yes M	1/0	1.2 (0.3 - 5.1)	•	0.024
IVII	400	Deference		0.024
	303			
$A \mathbf{P}$ (no stating use)	76	1.0 (1.1 - 2.3)	•	0.010
	70	Poforonco	1	0.019
	43			
AP (aton/astatin 20 mg)	218	3.1(1.2 - 0.1)		0 00
AF (alorvasialin 20 mg)	210 /18	Reference	i i	0.09
	40	17(09-33)		
AP (rosuvastatin 10 mg)	186	1.7 (0.9 - 3.3)	Ť	0.004
no	50	Reference	I	0.004
Ves	136	0.37 (0.18 - 0.74)	▲	
Hypertension (extreme risk)	480	0.07 (0.10 - 0.74)	Ť	< 0.001
no	288	Reference	I	\$ 0.001
Ves	192	27(19-41)	b	
CCU	480	2.7 (1.5 4.1)		0.341
no	381	Reference		0.041
Ves	99	1.3(0.8 - 2.1)	•	
ÂMI	480	1.0 (0.0 2.1)	¥	0 903
no	329	Reference		0.000
Ves	151	0.96(0.65 - 1.41)	•	
UAP	480		, I	0.205
no	95	Reference	I	0.200
Ves	385	0.72(0.45 - 1.15)	•	
HF	480		i	0.48
no	392	Reference	I	
ves	88	0.82 (0.51 - 1.31)	•	
NYHA classification	480		i i	0.408
Class I	105	Reference	I	
≥ Class II	375	0.81 (0.52 - 1.26)	•	
Killip classification	480	,	1	0.066
Class I	469	Reference		
≥ Class II	11	6.9 (0.9 - 53.2)	♦	
Secondary clinical outcome	480	. ,		0.222
no	82	Reference		
yes	398	0.71 (0.43 - 1.17)	•	
Primary clinical outcome	480		I	0.689
no	62	Reference	1	
yes	418	<u> 0.86 (0.50 - 1.49)</u>	• · · · · · · · · · · · · · · · · · · ·	
			0 25 50 75	

Table 1. Baseline characteristics of CVD with HBV and CVD alone participants.

Indices	CVD	HBV+CVD	t/χ^2	<i>P</i> -value
N	225	271	0.333	
age (years, mean ± SD)	60.21±10.41	59.90±10.18		0.739
Gender			4.463	0.035
Female [n (%)]	66(29.3%)	104(38.4%)		
Male [n (%)]	159(70.7%)	167(61.6%)		
Hypertension [n (%)]			0.328	0.567
No	75(33.3%)	97(35.8%)		
Yes	150(66.7%)	174(64.2%)		
DM [n (%)]			9.679	0.002
No	84(37.3%)	139(51.3%)		
Yes	141(62.7%)	132(48.7%)		
Smoking history [n (%)]			0.656	0.418
No	145(64.4%)	184(67.9%)		
Yes	80(35.5%)	87(32.1%)		
Drinking history [n (%)]			0.562	0.453
No	188(83.6%)	233(86.0%)		
Yes	37(16.4%)	38(14.0%)		
Height (cm)	167.00±7.19	165.00±8.42	1.900	0.058
Weight (kg)	70.42±10.46	68.25±12.23	2.038	0.042
BMI (kg/m ²)	25.23±3.22	24.68±3.76	1.66	0.098
Inpatient days (day)	3.70±1.68	4.12±2.91	-1.910	0.057
Pre-hospital medication [n (%)]			69.551	0.000
No	2(0.9%)	77(28.4%)		
Yes	223(99.1%)	194(71.6%)		
Statin use [n (%)]			11.102	0.011
No	2(0.9%)	16(5.9%)		
rosuvastatin	88(39.1%)	118(43.5%)		
atorvastatin	134(56.9%)	136(50.2%)		
simvastatin	1(0.4%)	1(0.4%)		
Dosage (mg/day)	16.87±7.43	15.55±6.59	2.037	0.042
NYHA classification [n (%)]			0.761	0.383
Ι	45(20%)	63(23.2%)		
II-IV	180(80%)	208(76.8%)		
Kililip classification [n (%)]			1.485	0.223
Ι	222(98.7%)	263(97.0%)		
II-IV	3(1.3%)	8(3.0%)		
Adverse event				
AMI [n (%)]			14.504	0.000
No	173(76.9%)	165(60.9%)		
Yes	52(23.1%)	106(39.1%)		

UAP [n (%)]			0.431	0.512
No	42(18.7%)	57(21%)		
Yes	183(81.3%)	214(79%)		
HF [n (%)]			3.092	0.079
No	190(84.4%)	212(78.2%)		
Yes	35(15.6%)	59(21.8%)		
LDL-C (mmol/L)	2.01±0.82	2.05±0.90	-0.418	0.676
TG (mmol/L)	1.45±0.83	1.26±0.75	2.678	0.008
HDL-C (mmol/L)	0.97±0.24	0.96±0.24	0.518	0.605
ApoA (g/L)	1.13±0.18	1.10±0.19	1.879	0.061
ApoB (g/L)	0.69±0.23	0.68±0.22	0.453	0.651
ApoE (mmol/L)	33.22±14.79	32.40±13.63	0.641	0.522
Lp(a) (mg/L)	330.17±296.68	262.34±247.03	2.767	0.006
TC (mmol/L)	3.66±1.01	3.54±1.00	1.309	0.191
non-HDL-C (mmol/L)	2.68±0.94	2.58±0.94	1.094	0.275
CYS-C (mg/L)	0.93±0.18	0.98±0.35	-1.906	0.057
LY (× $10^{9}/L$)	1.51±0.58	1.55±0.58	-0.711	0.478
MO (× $10^{9}/L$)	0.45±0.20	0.43±0.22	1.205	0.229
NE (× $10^{9}/L$)	4.72±1.76	4.42±1.95	1.794	0.073
PLT (× 10^9 /L)	208.41 ± 59.35	190.94 ± 61.39	3.195	0.001
NHR	5.19±2.38	4.99±2.76	0.811	0.418
MHR	0.50±0.27	0.49±0.36	0.312	0.755
NLR	3.66±2.35	3.99±2.76	1.165	0.245
PLR	153.20±63.91	139.16±73.53	2.236	0.026
THR	1.63±1.22	1.46±1.20	1.542	0.124
BNP (pg/L)	477.90±928.33	839.05±2948.05	-1.761	0.079
HbA1c (%)	6.49±1.24	6.43±1.35	0.453	0.651
HBsAg (IU/mL)	0.00 ± 0.00	208.15 ± 652.68	-4.787	0.000
HbsAb (mIU/mL)	62.44±137.92	3.99 ± 20.19	6.69	0.000
HBeAg (S/CO)	0.38±0.06	26.58 ± 179.70	-2.153	0.032
HBeAb (S/CO)	2.41±2.86	7.84 ± 1.07	1.008	0.314
HbcAb (S/CO)	2.41±2.86	7.84 ± 1.07	-28.16	0.000
ALT (U/L)	29.91±19.45	31.33 ± 19.74	-0.925	0.355
AST (U/L)	37.69 ± 66.37	41.57 ± 67.14	-0.642	0.521
AST/ALT	1.21 ± 0.96	1.26 ± 1.03	-0.548	0.584
TBil (µmol/L)	14.24 ± 6.83	14.97 ± 6.76	-1.164	0.245
ALP (U/L)	78.85 ± 2.94	$8\overline{4.83 \pm 92.29}$	-0.922	0.357

AMI, acute myocardial infarction; UAP, unstable angina pectoris; HF, heart failure; HbA1c, hemoglobin A1c; BNP, brain natriuretic peptide; ALT, glutamic-pyruvic transaminase; AST, glutamic oxalacetic transaminase; TBil, total bilirubin; ALP,

alkaline phosphatase; HBsAg, hepatitis B surface antigen; HbsAb, hepatitis B surface antibody; HBeAg, hepatitis E surface antigen; HbeAb, hepatitis E surface antibody; HbcAb, hepatitis B core antibody; TG, triglycerides; Lp(a), lipoprotein(a); PLR, platelet-to-lymphocyte ratio, PLT, platelet count; MO, Monocyte count; NE, neutrophil count; CVD, cardiovascular disease; HBV, hepatitis B virus; DM, diabetes mellitus; THR, thyroid hormone receptor; NHR, nuclear hormone receptor; MHR, monocyte-to-high-density lipoprotein-cholesterol ratio; LDL-C, low-density high-density lipoprotein cholesterol; HDL-C, lipoproteincholesterol; ApoA, apolipoprotein A; ApoB, apolipoprotein B; ApoE, apolipoprotein E; TC, total cholesterol; no-HDL-C, non-HDL cholesterol; CYS-C, cystatin C.

Statins	HBV infectio	n		.2	<i>P</i> -value
	negative	positive	Total (%)	X	(two-sided)
no use (pre-admission)	2 (2.5%)	77 (97.5%)	79 (100%)	76.835	0.000
atorvastatin	134 (59.6%)	91 (40.4%)	225 (100%)		
rosuvastatin	88 (46.3%)	102 (53.7%)	190 (100%)		
total	224	270	494		
OR (no use/atorvastatin)	0.018 (95% CI: 0.004 to 0.074)			76.904	0.000
OR (no use/rosuvastatin)	0.030 (95% CI: 0.007 to 0.126)			48.048	0.000
OR (atorvastatin/rosuvastatin)	1.940	(95% CI: 1.280 t	to 2.940)	9.979	0.002

Table 2. Relationship between statin use and HBV infection

Table 3. Relationship between statin use and quantitative parameters of HBV

Variables	Statins use	Ν	P50 (P25 – P75)	Mean ± SD	Range
HBsAg	No use=0	79	>250 (26 to >250)		<0.05 to >250
	atorvastatin =1	225	<0.05(<0.05 to 129)		<0.05 to >250
	rosuvastatin=2	190	2(<0.05 to 174)		<0.05 to >250
	measure		H = 65.606		
	Р		0.000		
Median Difference	e(0-1)		70(95% CI: 26 to 125)		
Median Difference	e(0-2)		63(95% CI: 18 to 117)		
Median Difference	e(1-2)		0(95% CI: 0 to 0)		
HBsAb	No use=0	73	0.58(0.20 to 1.45)	2.4±7.9	0 to 52
	atorvastatin =1	199	2.10(0.58 to 20.97)	48±133	0 to 951
	rosuvastatin=2	181	1.31(0.43 to 5.98)	21±57	0 to 338
	measure		H = 31.257		
	Р		0.000		
HBeAg	No use=0	73	0.34(0.31 to 0.42)	0.68±2.18	0.01 to 19
	atorvastatin =1	214	0.39(0.34 to 0.43)	9±111	0.01 to 1617
	rosuvastatin=2	186	0.39(0.34 to 0.43)	26±175	0.0225 to 1438
	measure		H = 8.044		
	Р		0.018		
HBeAb	No use=0	73	0.01(0.01 to 0.02)	0.20±0.48	0.01 to 2
	atorvastatin =1	214	0.86(0.02 to 1.76)	1.17±3.07	0 to 43
	rosuvastatin=2	186	0.47(0.01 to 1.74)	1.75±6.27	0.01 to 51
	measure		H = 47.239		
	Р		0.000		
HBcAb	No use=0	73	7.89(7.09 to 8.61)	7.69±1.57	0.06 to 10
	atorvastatin =1	214	6.06(0.16 to 7.62)	4.65±3.46	0.04 to 11
	rosuvastatin=2	186	7.02(0.62 to 8.04)	5.26±3.53	0.03 to 11
	measure		H = 47.295		
	Р		0.000		
HBV DNA	No use=0	42	129(<100 to 2103)		<10 to 11800000
	atorvastatin =1	121	<100(<100 to <100)		<10 to 1310000
	rosuvastatin=2	111	<100(<100 to <100)		<10 to 476000000
	measure		H = 5.522		

Р	0.063	
1	0.005	

Stating use		HbsAg quantificat	LT	D (two sided)		
Statins use	N	P50(P25–P75) Range			i (two-slucu)	
no use (pre-admission)	79	251(26 to >250)	<0.05 to >250			
atorvastatin (10 mg)	19	78(<0.05 to >250)	<0.05 to >250			
atorvastatin (20 mg)	182	<0.05 (<0.05 to 83)	<0.05 to >250			
atorvastatin (40 mg)	19	<0.05 (<0.05 to >250)	<0.05 to >250	-7.615	0.000	
rosuvastatin (10 mg)	8	17(<0.05 to 198)	<0.05 to >250			
rosuvastatin (20 mg)	166	1(<0.05 to 112)	<0.05 to >250			
rosuvastatin (40 mg)	12	80(<0.05 to >250)	<0.05 to >250	-5.936	0.000	

Table 4. Relationship between statin dose and HbsAg quantification.